Publications by authors named "Victoriya Finkel-Pekarsky"
Article Synopsis
- Lamotrigine is an antiepileptic drug also used for mood stabilization, with most studies suggesting it’s safe in pregnancy, though some data indicate a risk for oral clefts.
- This study compared the rates of major birth defects in pregnancies exposed to lamotrigine versus those with non-teratogenic drugs, finding similar anomaly rates in both groups.
- The research supports the use of lamotrigine during pregnancy, particularly as monotherapy, but emphasizes the need for further studies to fully understand risks, especially for oral clefts.
Objective: The authors conducted a prospective, comparative observational study to evaluate the risk of major anomalies following exposure to lithium during pregnancy.
Method: A total of 183 lithium-exposed pregnancies of women who contacted the Israeli Teratology Information Service were followed up (90.2% in the first trimester) and compared with 72 disease-matched and 748 nonteratogenic-exposed pregnancies.
After maternal exposure to mycophenolate in pregnancy a high number of fetal losses and a specific pattern of birth defects consisting of microtia, cleft lip, and other anomalies have been reported. However, so far, prospective data on pregnancy outcome allowing quantitative risk assessment are missing. We report on 57 prospectively ascertained pregnancies after maternal therapy with mycophenolate (mycophenolate mofetil or mycophenolate sodium) identified by European Teratology Information Services (ETIS) through their risk consultation process.
View Article and Find Full Text PDFObjective: To examine first trimester safety of angiotensin-converting-enzyme-inhibitors (ACEIs) or angiotensin-receptor-blockers (ARBs).
Study Design: Prospective observational cohort regarding pregnancy ACEI/ARBs-exposure including contacts to two Teratology Information Services in Israel (1994-2007) and Italy (1990-2008), with two comparison groups: (1) exposed to other antihypertensives (OAH) (2) after non-teratogenic exposure (NTE) in similar time frames.
Results: 252 ACEI/ARBs-exposed, 256 OAH-exposed and 495 NTE-exposed pregnancies were followed-up.
Objective: We sought to examine the fetal safety of colchicine.
Study Design: This was a prospective observational comparative cohort study regarding colchicine exposure during pregnancy including contacts to 2 Teratology Information Services in Israel from 1994 through 2006.
Results: In all, 238 colchicine-exposed pregnancies (97.